Chantada Guillermo, Doz François, Antoneli Celia B G, Grundy Richard, Clare Stannard F F, Dunkel Ira J, Grabowski Eric, Leal-Leal Carlos, Rodríguez-Galindo Carlos, Schvartzman Enrique, Popovic Maja Beck, Kremens Bernhard, Meadows Anna T, Zucker Jean-Michel
Department of Hematology-Oncology, Hospital JP Garrahan, Buenos Aires, Argentina.
Pediatr Blood Cancer. 2006 Nov;47(6):801-5. doi: 10.1002/pbc.20606.
Although intra-retinal tumor has long been staged presurgically according to the Reese-Ellsworth (R-E) system, retinoblastoma differs from other pediatric neoplasms in never having had a widely accepted classification system that encompasses the entire spectrum of the disease. Comparisons among studies that consider disease extension, risk factors for extra-ocular relapse, and response to therapy require a universally accepted staging system for extra-ocular disease.
A committee of retinoblastoma experts from large centers worldwide has developed a consensus classification that can encompass all retinoblastoma cases and is presented herein. Patients are classified according to extent of disease and the presence of overt extra-ocular extension. In addition, a proposal for substaging considering histopathological features of enucleated specimens is presented to further discriminate between Stage I and II patients.
The following is a summary of the classification system developed-Stage 0: Patients treated conservatively (subject to presurgical ophthalmologic classifications); Stage I: Eye enucleated, completely resected histologically; Stage II: Eye enucleated, microscopic residual tumor; Stage III: Regional extension [(a) overt orbital disease, (b) preauricular or cervical lymph node extension]; Stage IV: Metastatic disease [(a) hematogenous metastasis: (1) single lesion, (2) multiple lesions; (b) CNS extension: (1) prechiasmatic lesion, (2) CNS mass, (3) leptomeningeal disease]. A proposal is also presented for substaging of enucleated Stages I and II eyes.
The proposed staging system is the product of an international effort to adopt a uniform staging system for patients with retinoblastoma to cover the whole spectrum of the disease.
尽管视网膜内肿瘤长期以来在术前一直根据里斯 - 埃尔斯沃思(R - E)系统进行分期,但视网膜母细胞瘤与其他儿科肿瘤不同,它从未有过一个被广泛接受的涵盖疾病全谱的分类系统。对于考虑疾病扩展、眼外复发风险因素以及治疗反应的研究而言,需要一个针对眼外疾病的普遍接受的分期系统。
来自全球大型中心的视网膜母细胞瘤专家委员会制定了一种共识分类,该分类可涵盖所有视网膜母细胞瘤病例,现予公布。患者根据疾病范围和明显的眼外扩展情况进行分类。此外,还提出了一种考虑眼球摘除标本组织病理学特征的亚分期建议,以进一步区分I期和II期患者。
以下是所制定的分类系统总结——0期:接受保守治疗的患者(根据术前眼科分类);I期:眼球摘除,组织学上完全切除;II期:眼球摘除,显微镜下有残留肿瘤;III期:局部扩展[(a)明显的眼眶疾病,(b)耳前或颈部淋巴结扩展];IV期:转移性疾病[(a)血行转移:(1)单个病灶,(2)多个病灶;(b)中枢神经系统扩展:(1)视交叉前病变,(2)中枢神经系统肿块,(3)软脑膜疾病]。还提出了对I期和II期眼球摘除病例进行亚分期的建议。
所提议的分期系统是国际上为视网膜母细胞瘤患者采用统一分期系统以涵盖疾病全谱所做努力的成果。